Follow ZDNET: Add us as a preferred source on Google. As a person who covers consumer tech for a living, I get to use a few dozen smartphones every year. While I almost always advise on which is the ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the ...

I've been dabbling around with local LLMs on my computer for a while now. It all started as a hobby when I ran DeepSeek-R1 locally on my Mac, and is now a pretty amazing part of my workflow. I’ve ...

Want Google out of your life? It's pretty easy to find alternative search, email, and photo storage providers, but it's much harder to come up with a mobile operating system that's free of Google. The ...

Whether you're catching a train after the curtain call, squeezing multiple shows into one day, or just organizing your NYC itinerary, knowing the run time of Broadway performances is essential. In ...

Fullerton has launched its new city-operated ambulance transportation program. Under the model, fire personnel will manage the full emergency response, from initial patient contact to transport to a ...

A New Google Update Is Making Android Setup Less of a Chore Your email has been sent Ever feel like setting up a brand-new phone is a bit of a chore? Google just ...

For just $200, while I wish its performance was a bit better, the Samsung Galaxy A17 still outkicks its price. (Sam Rutherford for Engadget) Buying a good budget phone can be a challenge. High-end ...

MOBILE, Ala. (WALA) - The City of Mobile issued a press release saying it is accepting applications for a new $50 million loan program to support growth and create jobs. Here is the release: City ...

Jason Chun is a CNET writer covering a range of topics in tech, home, wellness, finance and streaming services. He is passionate about language and technology, and has been an avid writer/reader of ...

Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.